FindTrial
Sign In

Therapeutic efficacy of magnesium oxide for peripheral artery disease among patients undergoing hemodialysis - Open label randomized controlled trial

Therapeutic efficacy of magnesium oxide for peripheral artery disease among patients undergoing hemodialysis - Open label randomized controlled trial - Therapeutic efficacy of magnesium oxide for peripheral artery disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000024275
Enrollment
90
Registered
2016-12-15
Start date
2017-01-11
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral artery disease

Interventions

Intervention group: Magnesium oxide Administration period: 12 months Target range of serum magnesium levels: 2.7-3.3 mg/dL no treatment

Sponsors

Department of Comprehensive Kidney Disease Research, Osaka University Graduate School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients undergoing maintenance hemodialysis/hemodiafiltration and aged 20 years or older. 2. Patients with SPP of less than 80 mmHg. 3. Patients with gastroduodenal ulcer and/or gastritis and/or dyspepsia.

Exclusion criteria

Exclusion criteria: 1. Patients with serum magnesium levels of 3.4 mg/dL or greater. 2. Patients who had experienced side effects by magnesium oxide or rebamipide. 3. Patients currently taking magnesium oxide. 4. Patients suffering from critical limb ischemia. 5. Patients currently taking part in other interventional studies.

Design outcomes

Primary

MeasureTime frame
skin perfusion pressure—

Secondary

MeasureTime frame
ankle brachial index capillary analysis system bone turnover markers (bone alkaline phosphatase, TRACP-5b, parathyroid hormone)—

Countries

Japan

Contacts

Public ContactYusuke Sakaguchi

Osaka University Graduate School of Medicine Department of Comprehensive Kidney Disease Research

yusuke7771@gmail.com0668793857

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026